Testing a new drug combo for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a type of esophageal cancer called squamous cell carcinoma that cannot be surgically removed, has come back, or has spread
- You have had no more than one prior treatment for advanced disease (some groups require no prior treatment)
- You must provide a sample of your tumor for testing
- You are able to care for yourself and do light daily activities (ECOG score 0 or 1)
- You have not lost 10% or more of your body weight in the last month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a new drug combination for advanced esophageal squamous cell carcinoma that has stopped responding to prior treatment. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (SYS6010, enlonstobart, and chemotherapy) as a first treatment for people with advanced esophageal cancer that has not spread elsewhere. It aims to find a more effective option for patients who have not received prior therapy for their advanced disease.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.